GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (STU:UTH) » Definitions » E10

United Therapeutics (STU:UTH) E10 : €12.91 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is United Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

United Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was €5.676. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €12.91 for the trailing ten years ended in Mar. 2024.

During the past 12 months, United Therapeutics's average E10 Growth Rate was 14.90% per year. During the past 3 years, the average E10 Growth Rate was 15.30% per year. During the past 5 years, the average E10 Growth Rate was 12.30% per year. During the past 10 years, the average E10 Growth Rate was 20.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of United Therapeutics was 85.90% per year. The lowest was 8.60% per year. And the median was 28.70% per year.

As of today (2024-05-17), United Therapeutics's current stock price is €250.10. United Therapeutics's E10 for the quarter that ended in Mar. 2024 was €12.91. United Therapeutics's Shiller PE Ratio of today is 19.37.

During the past 13 years, the highest Shiller PE Ratio of United Therapeutics was 80.06. The lowest was 10.81. And the median was 21.54.


United Therapeutics E10 Historical Data

The historical data trend for United Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics E10 Chart

United Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.64 6.79 8.41 10.16 11.60

United Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.62 10.89 11.81 11.60 12.91

Competitive Comparison of United Therapeutics's E10

For the Biotechnology subindustry, United Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, United Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where United Therapeutics's Shiller PE Ratio falls into.



United Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, United Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=5.676/131.7762*131.7762
=5.676

Current CPI (Mar. 2024) = 131.7762.

United Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201406 1.546 100.560 2.026
201409 -0.411 100.428 -0.539
201412 1.760 99.070 2.341
201503 -0.333 99.621 -0.440
201506 1.702 100.684 2.228
201509 8.233 100.392 10.807
201512 1.928 99.792 2.546
201603 4.346 100.470 5.700
201606 3.907 101.688 5.063
201609 3.118 101.861 4.034
201612 2.304 101.863 2.981
201703 3.637 102.862 4.659
201706 -1.113 103.349 -1.419
201709 5.261 104.136 6.657
201712 0.363 104.011 0.460
201803 4.517 105.290 5.653
201806 3.407 106.317 4.223
201809 2.074 106.507 2.566
201812 1.301 105.998 1.617
201903 -10.018 107.251 -12.309
201906 4.124 108.070 5.029
201909 2.733 108.329 3.325
201912 1.080 108.420 1.313
202003 2.824 108.902 3.417
202006 2.140 108.767 2.593
202009 3.260 109.815 3.912
202012 1.800 109.897 2.158
202103 0.512 111.754 0.604
202106 3.030 114.631 3.483
202109 2.907 115.734 3.310
202112 2.080 117.630 2.330
202203 4.567 121.301 4.961
202206 2.280 125.017 2.403
202209 4.959 125.227 5.218
202212 2.520 125.222 2.652
202303 4.539 127.348 4.697
202306 4.837 128.729 4.952
202309 5.041 129.860 5.115
202312 3.998 129.419 4.071
202403 5.676 131.776 5.676

Add all the adjusted EPS together and divide 10 will get our e10.


United Therapeutics  (STU:UTH) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

United Therapeutics's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=250.10/12.91
=19.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of United Therapeutics was 80.06. The lowest was 10.81. And the median was 21.54.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


United Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of United Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


United Therapeutics (STU:UTH) Business Description

Traded in Other Exchanges
Address
1040 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

United Therapeutics (STU:UTH) Headlines

No Headlines